You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
HTG will leverage existing collaborations with firms including Illumina and Thermo Fisher Scientific to continue building in vitro diagnostic assays on their sequencers.
The high-throughput S2000 sequencer is the second instrument Genetron Health has received NMPA approval for, following the S5 benchtop instrument last year.
The rise of new protein analysis techniques have some questioning whether mass spec will in coming years retain its dominant position within proteomics.
While overall revenues and net income were up, analytical instruments revenues decreased 3 percent in Q4, and 2 percent organically.
Although Illumina's failure to acquire Pacific Biosciences stood out in 2019, the upward trend in M&A activity in the omics space in 2018 continued last year.
The federal court order dismissed the case with prejudice, which prevents the plaintiffs from raising the case again.
Highlights included mass spec-focused developments like data-independent acquisition and ion mobility along with platforms including Thermo Fisher's Q Exactive.
The company said it plans to use the platform for research and development of companion diagnostics and in other oncology and precision medicine applications.
The Korean company said it plans to use equipment and reagents from Thermo Fisher and to expand its overseas markets for CE sequencing services.
Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.
Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.
Science reports that a Dutch research funding agency is combating a ransomware attack.
In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.